Education
About Us
Working with TipRanks
Follow Us
Definium Therapeutics (DFTX)
NASDAQ:DFTX
Total Valuation
Definium Therapeutics has a market cap or net worth of $1.75B. The enterprise value is $1.45B.
Market Cap$1.75B
Enterprise Value$1.45B
Share Statistics
Definium Therapeutics has 99,698,130 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding99,698,130
Owned by Insiders2.55%
Owned by Institutions―
Financial Efficiency
Definium Therapeutics’s return on equity (ROE) is -0.55 and return on invested capital (ROIC) is -44.54%.
Return on Equity (ROE)-0.55
Return on Assets (ROA)-0.42
Return on Invested Capital (ROIC)-44.54%
Return on Capital Employed (ROCE)-0.45
Revenue Per Employee0.00
Profits Per Employee-2.48M
Employee Count74
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Definium Therapeutics is ―. Definium Therapeutics’s PEG ratio is -0.19.
PE Ratio―
PS Ratio0.00
PB Ratio3.60
Price to Fair Value3.60
Price to FCF-9.09
Price to Operating Cash Flow-9.75
PEG Ratio-0.19
Income Statement
In the last 12 months, Definium Therapeutics had revenue of 0.00 and earned -183.79M in profits. Earnings per share was -2.06.
Revenue0.00
Gross Profit0.00
Operating Income-166.31M
Pretax Income-183.79M
Net Income-183.79M
EBITDA-178.31M
Earnings Per Share (EPS)-2.06
Cash Flow
In the last 12 months, operating cash flow was -161.13M and capital expenditures 0.00, giving a free cash flow of -161.13M billion.
Operating Cash Flow-161.13M
Free Cash Flow-161.13M
Free Cash Flow per Share-1.62
Dividends & Yields
Definium Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.60
52-Week Price Change156.95%
50-Day Moving Average16.01
200-Day Moving Average11.52
Relative Strength Index (RSI)56.09
Average Volume (3m)1.66M
Important Dates
Definium Therapeutics upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Definium Therapeutics as a current ratio of 6.29, with Debt / Equity ratio of 0.00%
Current Ratio6.29
Quick Ratio6.29
Debt to Market Cap0.00
Net Debt to EBITDA1.45
Interest Coverage Ratio-30.34
Taxes
In the past 12 months, Definium Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Definium Therapeutics EV to EBITDA ratio is -5.26, with an EV/FCF ratio of -7.13.
EV to Sales0.00
EV to EBITDA-5.26
EV to Free Cash Flow-7.13
EV to Operating Cash Flow-7.13
Balance Sheet
Definium Therapeutics has $411.59M in cash and marketable securities with $0.00 in debt, giving a net cash position of $411.59M billion.
Cash & Marketable Securities$411.59M
Total Debt$0.00
Net Cash$411.59M
Net Cash Per Share$4.13
Tangible Book Value Per Share$3.50
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Definium Therapeutics is $37.27, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$37.27
Price Target Upside112.36% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast―
EPS Growth Forecast0.69%